Michael Ibrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Ibrahim has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- David T. Weaver
Thomas Jefferson University, Philadelphia, PA, USA
25 shared publications - Gerardo Ferrer
Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain
25 shared publications - Jacqueline Claudia Barrientos
Department of Hematology/Oncology, Mount Sinai Comprehensive Cancer Center, Miami Beach, FL 33140, USA
25 shared publications - Jeffery L. Kutok
Epizyme Inc., Cambridge, Massachusetts
25 shared publications - Jonathan A. Pachter
Verastem Oncology, Needham, MA 02494, USA
25 shared publications - Kanti R. Rai
The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY 11030, USA
25 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Effects of treatment with duvelisib and ibrutinib on the numbers of T cells in in mice receiving samples from the same patients in Figure 6.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Effects of treatment with duvelisib and ibrutinib on the numbers of T cells in in mice receiving samples from the same patients in Figure 6.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Distinct actions of PI3K-δ and PI3K-γ on human cytokines in PDX model of U-CLL and M-CLL patients.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Distinct actions of PI3K-δ and PI3K-γ on human cytokines in PDX model of U-CLL and M-CLL patients.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Effects of inhibition of PI3K isoforms on CLL-cell proliferation, survival, and migration.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Effects of inhibition of PI3K isoforms on CLL-cell proliferation, survival, and migration.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
IC50 values of PI3K isoform inhibitors used. Duvelisib5, IPI-3063 (PI3K-d inhibitor)5, IPI-549 (PI3K-g inhibitor used in vitro)50, IPI-5243 (PI3K-g inhibitor used in vivo).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
IC50 values of PI3K isoform inhibitors used. Duvelisib5, IPI-3063 (PI3K-d inhibitor)5, IPI-549 (PI3K-g inhibitor used in vitro)50, IPI-5243 (PI3K-g inhibitor used in vivo).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Distinct actions of PI3K-δ and PI3K-γ on mouse cytokines in PDX model of U-CLL and M-CLL patients.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Distinct actions of PI3K-δ and PI3K-γ on mouse cytokines in PDX model of U-CLL and M-CLL patients.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Distinct actions of PI3K-δ and PI3K-γ on numbers of immune cells in CLL.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Distinct actions of PI3K-δ and PI3K-γ on numbers of immune cells in CLL.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Effects of PI3K-gi, PI3K-di on the proliferation and migration of CLL-derived T cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Effects of PI3K-gi, PI3K-di on the proliferation and migration of CLL-derived T cells.
- Open Access
- 15 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Effects of PI3K-gi, PI3K-di on the proliferation and migration of CLL-derived T cells.
- 15 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Effects of PI3K-gi, PI3K-di on the proliferation and migration of CLL-derived T cells.
- Open Access
- 15 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Effects of inhibition of PI3K isoforms on CLL-cell proliferation, survival, and migration.
- 15 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Effects of inhibition of PI3K isoforms on CLL-cell proliferation, survival, and migration.
- Open Access
- 15 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Distinct actions of PI3K-δ and PI3K-γ on numbers of immune cells in CLL.
- 15 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Distinct actions of PI3K-δ and PI3K-γ on numbers of immune cells in CLL.